vonoprazan + tripotassium dicitrate bismuthate + amoxicillin

This investigational triple therapy combination consists of vonoprazan, tripotassium dicitrate bismuthate, and amoxicillin, and is being studied by Kaohsiung Medical University for the treatment of Helicobacter pylori infection. Vonoprazan is a potassium-competitive acid blocker (P-CAB) that provides rapid and sustained inhibition of the gastric H+-K+ ATPase, creating an optimal pH environment for antibiotic activity. Tripotassium dicitrate bismuthate is a bismuth salt that exerts direct antimicrobial effects against H. pylori, prevents bacterial adhesion to the gastric mucosa, and enhances the efficacy of co-administered antibiotics. Amoxicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. This regimen is designed as a simplified alternative to traditional bismuth-based quadruple therapies, aiming to maintain high eradication rates with a reduced antibiotic burden.

Other names

bismuth-amoxicillin-vonoprazan triple therapyBAV triple therapyvonoprazan, tripotassium dicitrate bismuthate, amoxicilline